Abstract
The concept that hypertension and chronic kidney disease (CKD) originate in early life has emerged recently. During pregnancy, tryptophan is crucial for maternal protein synthesis and fetal development. On one hand, impaired tryptophan metabolic pathway in pregnancy impacts fetal programming, resulting in the developmental programming of hypertension and kidney disease in adult offspring. On the other hand, tryptophan-related interventions might serve as reprogramming strategies to prevent a disease from occurring. In the present review, we aim to summarize (1) the three major tryptophan metabolic pathways, (2) the impact of tryptophan metabolism in pregnancy, (3) the interplay occurring between tryptophan metabolites and gut microbiota on the production of uremic toxins, (4) the role of tryptophan-derived metabolites-induced hypertension and CKD of developmental origin, (5) the therapeutic options in pregnancy that could aid in reprogramming adverse effects to protect offspring against hypertension and CKD, and (6) possible mechanisms linking tryptophan metabolism to developmental programming of hypertension and kidney disease.
| Original language | English |
|---|---|
| Article number | 8705 |
| Pages (from-to) | 1-21 |
| Number of pages | 21 |
| Journal | International Journal of Molecular Sciences |
| Volume | 21 |
| Issue number | 22 |
| DOIs | |
| State | Published - 02 11 2020 |
Bibliographical note
Publisher Copyright:© 2020 by the authors. Licensee MDPI, Basel, Switzerland.
Keywords
- Aryl hydrocarbon receptor
- Chronic kidney disease
- Developmental origins of health and disease (DOHaD)
- Hypertension
- Indole
- Kynurenine
- Melatonin
- Serotonin
- Tryptophan
- Uremic toxin
